Latest News

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Wesfarmers Limited ( ASX:WES ) saw significant share price movement during recent months on the ASX, rising to highs of...

Market forces rained on the parade of Sunteck Realty Limited ( NSE:SUNTECK ) shareholders today, when the analysts...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Hindustan...

The recent earnings posted by Network18 Media & Investments Limited ( NSE:NETWORK18 ) were solid, but the stock didn't...

We wouldn't blame ICICI Bank Limited ( NSE:ICICIBANK ) shareholders if they were a little worried about the fact that...

Why Eastern Bankshares (EBC) Is On Investors’ Radar Today Eastern Bankshares (EBC) is drawing attention after recent trading, with the share price closing at US$19.90 and showing mixed returns over the past week, month, and past 3 months. See our latest analysis for Eastern Bankshares. Even after a 2.97% one day share price decline and 5.46% 7 day share price pullback to US$19.90, Eastern Bankshares still shows positive year to date share price momentum alongside strong multi year total...

Genesis Energy (NZSE:GNE) has committed to a second stage of battery storage at Huntly Power Station, approving a 100MW / 200MWh expansion that supports its Gen35 plan and shift away from baseload gas. See our latest analysis for Genesis Energy. The Huntly BESS expansion comes as Genesis Energy’s 1 month share price return of 8.8% and 7 day return of 4.4% contrast with a year to date share price decline of 2.1%. At the same time, the 1 year total shareholder return of 17.1% and positive 3...

World Kinect Corporation reported past first-quarter 2026 results with sales of US$9.69 billion, net income of US$26.2 million and a swing from loss to earnings per share, alongside completing a sizeable share repurchase under its 2024 buyback program. The quarter’s earnings and revenue were well ahead of analyst expectations, powered by strong Marine and Aviation performance and management’s ongoing portfolio simplification efforts despite continued weakness in the Land segment. We’ll now...

As you might know, Tips Music Limited ( NSE:TIPSMUSIC ) just kicked off its latest annual results with some very strong...

Those following along with XMH Holdings Ltd. ( SGX:BQF ) will no doubt be intrigued by the recent purchase of shares by...

We'd be surprised if Centuria Capital Group ( ASX:CNI ) shareholders haven't noticed that the Independent Non-Executive...

Wondering if ABB, at a last close of CHF 77.90, still offers value after such a strong run, or if you are arriving late to the story. The share price performance has been strong, with returns of 3.2% over 7 days, 23.4% over 30 days, 27.2% year to date, 82.8% over 1 year, 156.1% over 3 years and 207.8% over 5 years. This naturally raises questions about risk and upside from here. Recent coverage has focused on ABB's position in electrification, automation and power grid technology, which ties...

This article examines whether Iovance Biotherapeutics at US$3.44 offers value or mainly adds extra risk by breaking down what the current share price might be indicating. The stock has seen mixed returns, with a 10.9% decline over the last 7 days and a 2.0% decline over the past year, alongside a 36.5% gain year to date, a 39.0% decline over 3 years, and an 89.1% decline over 5 years. Recent attention on Iovance Biotherapeutics has put its share price movements in sharper focus for investors...

Biohaven has completed enrollment for its Phase 2 proof of concept trial evaluating obesity drug candidate taldefgrobep alfa. The study is assessing taldefgrobep alfa as a potential monotherapy and in combination with standard care. The company has indicated that topline results from the trial are expected later in the year. For investors tracking NYSE:BHVN, this update adds a fresh angle to a story often centered on its neurology pipeline. The stock closed at $9.88, with a 30 day return of...

StoneX Financial Europe GmbH has introduced a new Fat Filled Milk Powder contract as part of a broader OTC dairy derivatives suite developed with Expana. The launch extends StoneX Group's risk management offering for dairy clients in Europe, providing an additional tool for handling price volatility. The development highlights further product expansion beyond traditional financial instruments within StoneX Group's trading solutions. For investors watching StoneX Group (NasdaqGS:SNEX), the...

If you are wondering whether Crocs at around US$102 per share still offers value, it helps to step back and separate the recent excitement from what the business may be worth. The stock has had a mixed run, with a 3.4% decline over the last 7 days, a 28.6% gain over the last 30 days, a 17.7% return year to date, and a 4.8% return over the last year, set against weaker 3 year and 5 year returns of 17.3% and 2.2% respectively. These shifts have drawn more attention to how the market is...

Western Union (WU) opened 2026 with Q1 revenue of US$982.7 million and basic EPS of US$0.21, alongside net income of US$64.7 million, providing a clear snapshot of its recent financial performance. The company reported quarterly revenue of US$983.6 million and EPS of US$0.37 in Q1 2025, compared with US$982.7 million and EPS of US$0.21 in Q1 2026. Trailing twelve month EPS stands at US$1.37 on revenue of about US$4.0 billion, leaving investors focused on how the current margin profile shapes...

Henderson Land Development (SEHK:12) has released its FY 2025 results with second half revenue of HK$16.2b and basic EPS of HK$0.57, setting the tone for how investors will read the year at a share price of HK$30.36. The company has seen half year revenue move from HK$13.5b with EPS of HK$0.64 in 2H FY 2024 to HK$16.2b with EPS of HK$0.57 in 2H FY 2025, while trailing 12 month EPS now stands at HK$1.17 on revenue of HK$25.7b. The focus is therefore on how margins and profit quality shape the...

SES AI (SES) has just posted Q1 2026 results with revenue of US$6.7 million, a basic EPS loss of US$0.04, and a net income loss of US$12.1 million. This sets a clear tone for how much growth is currently coming at the expense of profitability. Over the past year, the company has seen quarterly revenue move from US$5.8 million in Q1 2025 to US$6.7 million in Q1 2026. Quarterly basic EPS losses have ranged between US$0.04 and US$0.11, underscoring a business still investing heavily to scale...

H. Lundbeck (CPSE:HLUN B) shares are in focus after the company reported new 6 month real world INFUSE study results for migraine drug eptinezumab at the American Academy of Neurology 2026 meeting. See our latest analysis for H. Lundbeck. The eptinezumab data arrives at a time when H. Lundbeck’s short term momentum is positive, with a 14.59% 1 month share price return and a 54.44% 1 year total shareholder return. However, the 90 day share price return of 2.16% decline suggests some earlier...

Wondering if West Pharmaceutical Services at around US$306 is priced for perfection or leaving something on the table for new investors? This article walks through what the current market price might be saying about value. The stock has delivered returns of 11.8% over the last 7 days, 25.8% over the last 30 days, 10.8% year to date and 43.2% over the last year. However, the 3 year and 5 year returns of negative 14.6% and negative 5.7% show a very different experience for anyone who held...

Frasers Centrepoint Trust recently reported half-year results to March 31, 2026, with sales rising to S$221.87 million and net income to S$124.35 million, alongside higher basic and diluted earnings per share versus a year earlier. The combination of stronger revenue and earnings underscores the REIT’s ability to grow income while maintaining profitability across its largely necessity-focused suburban mall portfolio. With this earnings improvement in mind, we’ll now examine how the stronger...

Kalray earnings: narrowing loss alongside lower revenue Kalray (ENXTPA:ALKAL) has drawn fresh attention after reporting full year 2025 results, with revenue and sales below the prior year, while the net loss narrowed compared with 2024. See our latest analysis for Kalray. The earnings release comes after a sharp shift in market sentiment, with the share price at €8.35 and a 30 day share price return of 146.68%, alongside a very large 1 year total shareholder return and weak 3 year and 5 year...